Cerus 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Cerus reported Q3 2026 product revenue of $57.7 million, up 10% from Q3 2025, and product revenue for the first nine months of 2026 of $168.8 million, up 14% from the first nine months of 2025.
- North American product revenue increased 12% year over year, while EMEA product revenue, as reported, increased 5%; unfavorable foreign currency exchange rates negatively impacted reported EMEA revenue growth by approximately 2%.
- North American platelet kit and calculated platelet doses increased 5% year over year, outpacing underlying platelet market growth.
- IFC product revenue was $5.6 million in Q3 2026, compared with $3.9 million in Q3 2025; 90% of IFC sales shipped during the quarter were in kit form, and dose-equivalent IFC sales volume increased 7% sequentially.
- Product gross margin was 52.4%, compared with 53.4% in Q3 2025 and 51.4% in Q2 2026.
- Total operating expenses were $36.2 million, up from $34.4 million in Q3 2025, while operating expenses increased 5% compared with product revenue growth of 10%.
- GAAP net loss attributable to Cerus was under $1 million, approaching break-even, and non-GAAP adjusted EBITDA was $5.7 million, compared with $5 million a year earlier, marking the 10th consecutive quarter of positive adjusted EBITDA.
- Cash generation from operations was $3 million, and cash, cash equivalents, and short-term investments were $57.1 million as of September 30, 2026, up close to $1 million from June 30.
- Cerus announced positive top-line results from its Phase III RETA study: the trial met its primary efficacy endpoint by demonstrating noninferiority in adjusted hemoglobin increment, and there was no statistically significant difference between treatment and control arms in treatment-emergent adverse events.
- The RETA study's intercept RBC-specific antibodies were consistent with prior studies and resulted in no clinical impact.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker, Tim Lee, Head of Investor Relations.
Please go ahead. Thank you and good afternoon.
I'd like to thank everyone for joining us today. As part of today's webcast, we are simultaneously displaying slides that you can follow. You can access the slides from the Investor Relations website at ir.cerus.com. With me on the call are Vivek Jayaraman, Cerus' President and Chief Executive Officer, Kevin Green, Cerus' Chief Financial Officer, and Dr. Nina Mufti, Cerus' Senior Vice President, Research and Development. Cerus issued two press releases this afternoon, one announcing our financial results for the third quarter ended September 30, 2026, and describing the company's recent business highlights. The other announcing top-line results from our phase III RedeS study. You can access copies of both announcements on the company's website at www.cerus.com.
I'd like to remind you that some of the statements we will make on this call relate to future events and performance rather than historical facts and are forward-looking statements. These include statements regarding financial outlook and performance, our business strategy and priorities, expected growth and market opportunities, clinical and regulatory activities, product launches and expansion, and other statements that are not historical fact. These forward-looking statements involve risks and uncertainties that can cause actual performance and results to differ materially. Please refer to the forward-looking statement slide accompanying today's webcast, today's press releases, and risk factors in our Form 10-Q for the quarter ended September 30, 2026, which we will file shortly, for important factors that can cause actual results to differ materially. We undertake no duty or obligation to update our forward-looking statements. On today's call, we will also be discussing non-GAAP financial measures, including non-GAAP adjusted EBITDA.
These non-GAAP measures should be considered a supplement to and not a replacement for measures presented in accordance with GAAP. For a reconciliation of non-GAAP financial measures to the most comparable GAAP financial measures, to the extent reasonably available, please refer to today's press release and the slide presentation available on our website. We'll begin today with Vivek providing a business update and corporate highlights, followed by Kevin to review our financial results and expectations for the rest of 2026, and lastly, closing remarks from Vivek. And now, it's my pleasure to introduce Vivek Jayaraman, Cerus' President and Chief Executive Officer.
Thank you, Tim, and good afternoon, everyone. We appreciate you joining us today. At Cerus, our mission is clear: to expand patient access to safer blood and establish INTERCEPT as the standard of care for transfused blood components globally. Our third quarter kit sales represent nearly 800,000 doses of transfusible blood. Each dose represents a step toward improving patient care and enable us to extend the reach of pathogen reduction technology globally. Earlier today, we announced positive top-line results from our Phase III RedeS study. This is another important step toward extending our pathogen reduction technology to red blood cell transfusion. Reflecting on my first quarter as CEO, I am more confident than ever in our team, our technology, and the opportunities ahead. As noted, our mission is to establish INTERCEPT as the standard of care for transfused blood components globally.
Realizing this mission requires us to drive sustained growth, deliver meaningful innovation, and build a financially strong business that can self-fund ongoing product and technology advancements. From an operating perspective, we are focused on three core priorities that support our mission: delivering sustainable double-digit annual growth, advancing clinical and technological innovation, and strengthening our financial foundation. Our third quarter performance reflects meaningful progress across all three priorities. Furthermore, the team executed well despite having to deal with a dynamic geopolitical and macroeconomic environment that created some near-term headwinds. Taken together, our quarterly performance demonstrates the value of our product and geographic breadth, along with the resilience of our team and their ability to navigate near-term obstacles. We are generating strong growth across our core franchises, are successfully transitioning our IFC business model, and our international rollout of the INT200 illuminator is exceeding expectations.
With the completion of our Phase III RedeS trial, we have built the largest library of clinical evidence in support of pathogen reduction technology in red cell transfusion. Financially, we delivered our 10th consecutive quarter of positive adjusted EBITDA, improved our margins, and generated $3 million in positive cash flow. I am proud of our team's performance this quarter. We will now discuss each of these three pillars in further detail. Worldwide product revenue increased 10% year over year, with U.S. performance leading the way. We witnessed continued momentum in our IFC franchise, as well as gains in our core platelet franchise that solidly outpaced underlying market growth. International placements of the INT200 illuminator also contributed to growth and helped set the foundation for further kit penetration. North American sales increased 12% and accounted for just over two-thirds of third quarter product revenue.
INTERCEPT for platelets continues to be the standard of care in both the United States and Canada. In fact, INTERCEPT platelets are now used at all leading U.S. hospitals that are recognized in the latest U.S. News & World Report rankings. Our collaboration with Blood Centers of America, or BCA, is helping broaden adoption. As a reminder, we entered into a nationwide agreement with BCA at the beginning of this year, and BCA member blood centers account for more than half of all blood products distributed in the U.S. While many BCA members were already Cerus customers, the agreement has created opportunities to deepen those relationships while also allowing us to secure new customers across both platelets and IFC. Through the first three quarters of the year, revenue growth from BCA member blood centers outpaced overall North American growth.
Turning to IFC, hospital demand continues to increase as our value proposition gains traction. Immediate access to INTERCEPT and a 5-day post-thaw shelf life offer compelling benefits to clinicians, hospital administrators, and most importantly, patients. The longer shelf life can materially reduce waste, while the availability of pre-thawed IFC can support more timely treatment in critical bleeding situations. Medical education remains important to expanding adoption. At the recent Association for the Advancement of Blood & Biotherapies annual meeting, the team from Grady Memorial Hospital Atlanta shared their real-world experience with the INTERCEPT Blood System, including IFC. The team at Grady first adopted IFC in September 2025. Now they keep a unit of IFC thawed at all times, ready to be issued. Peer-to-peer exchanges are incredibly valuable and help clinicians learn from one another and better understand how IFC can fit into their clinical practice.
We are also evolving our IFC commercial model to support broader patient access and more attractive economics. We are migrating from direct hospital sales to distribution via our blood center customers. I am pleased with the progress we made in Q3 with respect to the pronounced mix shift from finished goods to kit sales. Kits carry lower unit prices, but offer more attractive gross margins and enable us to leverage the blood center's distribution network, which greatly expands our hospital and patient reach. On a dose equivalent basis, IFC sales volume increased 7% sequentially. We are seeing continued strong performance in IFC as we approach year-end and are highly confident that our IFC franchise will be a meaningful growth driver for years to come. In EMEA, our commercial organization continues to deliver solid performance in an increasingly challenging environment.
Geopolitical conflicts in the Middle East and Russia, along with a strengthened U.S. dollar, created some near-term headwinds. We believe these headwinds are transient and that the underlying opportunity for our international business remains attractive. Unit placements of INT200 in EMEA have exceeded our expectations and contributed strongly to the third quarter sales. We expect that trend to continue in the fourth quarter, and I appreciate the international team's unwavering focus on customer support. Our second priority, advancing innovation, builds on our commitment to drive clinical and technological advances that improve transfusion medicine. New products and expanded indications can bring INTERCEPT to more patients and increase our addressable markets. This afternoon, we announced positive top-line results from our phase III RedeS trial of the INTERCEPT Blood System.
Completing the study is a significant milestone in advancing our progress to extend the application of our pathogen reduction technology to red cell transfusions. We are grateful to the patients, investigators, blood centers, and Cerus colleagues whose commitment made this important study possible. Over the past decade, pathogen reduction has become an integral part of the blood safety toolkit for platelets, plasma, and IFC. We believe extending pathogen reduction to red blood cell transfusions represents an important opportunity to further improve transfusion safety and expand the reach of our technology. RedeS compared the safety and efficacy of INTERCEPT-treated red blood cells with conventional red blood cells in patients requiring acute and long-term transfusion support. The study assessed the primary efficacy endpoint and two primary safety endpoints. RedeS met its primary efficacy endpoint, demonstrating non-inferiority in adjusted hemoglobin increment compared with conventional red blood cells.
Adjusted hemoglobin increment is a commonly used measure of RBC transfusion effectiveness. In addition, when evaluating treatment-emergent adverse events in the RedeS top-line results, including the INTERCEPT RBC-specific antibodies seen in the treatment arm, there was no statistically significant difference between the treatment and control arms. The antibodies seen were consistent with prior studies and resulted in no clinical impact. The RedeS top-line findings add to the clinical evidence from the STARS, SPARC, and ReCePI trials. We are encouraged by the efficacy results and will complete the full clinical analysis to further characterize the study's findings over the coming months. With respect to our CE mark red cell filing, ANSM continues to review our application. We recently held a constructive meeting with ANSM and are preparing responses to the questions they raised. As part of our response, we will include a full RedeS clinical study report.
The decision to include the RedeS data into our package was well received by ANSM and will provide more clinical evidence, thereby strengthening our submission. As such, we now expect CE mark clearance in late 2027. Pending CE mark approval, we are planning for a limited market release targeting centers of excellence in Europe. Our initial focus will be a small number of leading blood centers, with the goal of generating real-world experience, which will inform our broader go-to-market strategy and approach. Turning to the U.S., we received preliminary feedback and questions from the FDA on our PMA platelet submission for the INT200 illuminator. We believe these questions are addressable, although the scope will require us to gather some additional data. We will have more visibility on approval timing once we align with the agency on the scope of these incremental data requirements.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
8 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
